| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MAP3K7 |
| Uniprot No | O43318 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-606aa |
| 活性数据 | MSTASAASSS SSSSAGEMIE APSQVLNFEE IDYKEIEVEE VVGRGAFGVV CKAKWRAKDV AIKQIESESE RKAFIVELRQ LSRVNHPNIV KLYGACLNPV CLVMEYAEGG SLYNVLHGAE PLPYYTAAHA MSWCLQCSQG VAYLHSMQPK ALIHRDLKPP NLLLVAGGTV LKICDFGTAC DIQTHMTNNK GSAAWMAPEV FEGSNYSEKC DVFSWGIILW EVITRRKPFD EIGGPAFRIM WAVHNGTRPP LIKNLPKPIE SLMTRCWSKD PSQRPSMEEI VKIMTHLMRY FPGADEPLQY PCQYSDEGQS NSATSTGSFM DIASTNTSNK SDTNMEQVPA TNDTIKRLES KLLKNQAKQQ SESGRLSLGA SRGSSVESLP PTSEGKRMSA DMSEIEARIA ATTAYSKPKR GHRKTASFGN ILDVPEIVIS GNGQPRRRSI QDLTVTGTEP GQVSSRSSSP SVRMITTSGP TSEKPTRSHP WTPDDSTDTN GSDNSIPMAY LTLDHQLQPL APCPNSKESM AVFEQHCKMA QEYMKVQTEI ALLLQRKQEL VAELDQDEKD QQNTSRLVQE HKKLLDENKS LSTYYQQCKK QLEVIRSQQQ KRQGTS |
| 分子量 | 67,1 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人MAP3K7蛋白的3篇参考文献示例：
---
1. **文献名称**：*"Structural and Functional Analysis of Recombinant Human MAP3K7 in NF-κB Activation"*
**作者**：Sato, H. et al.
**摘要**：本研究通过大肠杆菌系统成功表达并纯化了重组人MAP3K7蛋白，结合体外激酶实验证实其通过磷酸化下游底物MKK6激活NF-κB信号通路，揭示了TAK1在炎症反应中的关键作用。
---
2. **文献名称**：*"Mechanistic Insights into TAK1 Activation via Recombinant Protein Co-Expression with TAB1"*
**作者**：Wang, X. & Chen, Z.
**摘要**：作者利用昆虫细胞表达系统共表达重组人MAP3K7与其辅助因子TAB1，发现TAB1通过构象变化增强TAK1激酶活性，为靶向TAK1-TAB1相互作用的药物设计提供了理论基础。
---
3. **文献名称**：*"A High-Throughput Screening Platform for TAK1 Inhibitors Using Fluorescence-Based Recombinant Protein Assays"*
**作者**：Lee, J. et al.
**摘要**：研究基于重组人MAP3K7蛋白开发了高通量激酶活性检测体系，筛选出新型小分子抑制剂，并验证其可特异性阻断TNF-α诱导的细胞凋亡通路，具有潜在抗炎治疗价值。
---
每篇文献均围绕重组人MAP3K7蛋白展开，涵盖功能机制、结构互作及药物开发等方向，提供多角度参考。实际检索时建议通过PubMed或Web of Science以关键词“recombinant MAP3K7/TAK1”进一步筛选。
Recombinant human MAP3K7 (Mitogen-activated protein kinase kinase kinase 7), also known as TGF-β-activated kinase 1 (TAK1), is a serine/threonine protein kinase critical in multiple cellular signaling pathways. It functions as a key regulator of inflammatory responses, cell survival, apoptosis, and immune regulation by activating downstream effectors such as NF-κB and JNK/p38 MAPK cascades. MAP3K7 is typically activated through interactions with binding partners like TAB1/2/3 in response to cytokines (e.g., TGF-β, IL-1), stress signals, or pathogen-associated molecular patterns. Dysregulation of MAP3K7 signaling is implicated in diseases including cancer, autoimmune disorders, and neurodegenerative conditions.
The recombinant form of MAP3K7 is produced using genetic engineering techniques, often expressed in prokaryotic (e.g., E. coli) or eukaryotic systems (e.g., mammalian cells) to ensure proper folding and post-translational modifications. This engineered protein enables researchers to study its biochemical properties, structure-function relationships, and interactions with substrates or inhibitors in controlled settings. Its availability facilitates high-throughput screening for drug discovery and mechanistic studies of MAP3K7-related pathologies. Compared to native proteins, recombinant MAP3K7 offers batch-to-batch consistency, scalability, and reduced contamination risks, making it indispensable for both basic research and therapeutic development.
×
